<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[chinabio today Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/chinabio+today.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to chinabio today]]></description>
	<s:counts start="0" returned="20" found="278" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Biostar Pharma Announces $1 Million Acquisition of Medical Equipment Manufacturer]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F178816-biostar-pharma-announces-1-million-acquisition-of-medical-equipment-manufacturer%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  Biostar Pharmaceuticals (BSPM.OB) of Xianyang has signed a letter of intent to acquire an unnamed Xi'an-based manufacturer of medical equipment and nutrients for $1.1 million in cash. Biostar expects the transaction will create an additional $3 million of revenue in 2010. The acquisition represents Biostar&#8217;s first...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 18 Dec 2009 01:00:13 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
	</item>
	<item>
		<title><![CDATA[Novartis Increases China Commitment: Opens Suzhou Plant, Technical R&D Center]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F178501-novartis-increases-china-commitment-opens-suzhou-plant-technical-r-d-center%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  In November, Novartis (NYSE: NVS) held the official opening of Suzhou Novartis Pharma Technology Co., the company&#8217;s new $250 million center devoted to technical R&D as well as manufacturing of APIs and intermediates. Novartis says the facility is a &#8220;complement&#8221; to its existing global network of...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 16 Dec 2009 09:45:11 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">NVS</category>
	</item>
	<item>
		<title><![CDATA[Pfizer Gains Presence in Diabetes Market with Takeda Deal]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F178431-pfizer-gains-presence-in-diabetes-market-with-takeda-deal%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  Pfizer (NYSE: PFE) has taken on the job of co-promoting a diabetes drug in China for Takeda Pharmaceutical Company. Actos pioglitazone HCl, an oral treatment for diabetes 2, produces over $4 billion of annual revenues for Takeda worldwide. The agreement will be in force until 2020...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 16 Dec 2009 02:52:47 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Lilly Aims at China?s Growing Pharmaceutical Market]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F178009-lilly-aims-at-chinas-growing-pharmaceutical-market%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  In an annual review of its business plans, Eli Lilly NYSE LLY revealed China&#8217;s pharmaceutical market will be a top priority for the company. Lilly has reorganized its corporate structure so that one of its six units would be devoted to emerging markets, and this unit...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 14 Dec 2009 01:56:14 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
		<category domain="tickers">LLY</category>
	</item>
	<item>
		<title><![CDATA[Merck Starts China Trial of Cancer Vaccine]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F178005-merck-starts-china-trial-of-cancer-vaccine%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  Merck KGaA MRK of Germany will conduct a multi-national Phase III clinical trial of the therapeutic cancer vaccine Stimuvax in Asian patients. The trial will enroll 420 patients with advanced non-small cell lung cancer NSCLC in five Asian countries: China, Hong Kong, South Korea, Singapore and...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 14 Dec 2009 01:39:05 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Disappointing Pricing for China Nuokang?s IPO]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F177682-disappointing-pricing-for-china-nuokangs-ipo%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:         China Nuokang Bio-Pharmaceutical (NSDQ: NKBP) priced its IPO at $9, which was slightly below the expected range of $10-$12. When the shares began trading Thursday, they fell further, dropping 56 cents to $8.44, a loss of about 6%. The...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 10 Dec 2009 11:37:17 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
	</item>
	<item>
		<title><![CDATA[Pfizer Forms Cancer Collaboration with Crown Bioscience]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F177680-pfizer-forms-cancer-collaboration-with-crown-bioscience%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  Crown Bioscience, a pre-clinical CRO providing biology services for oncology indications, will collaborate with Pfizer (NYSE: PFE) to research and develop novel drugs for cancers that are prevalent in Asia and remain unaddressed medical needs. Crown will receive an upfront payment and research funding, as well...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 10 Dec 2009 11:31:11 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Milestone Scientific Forms China JV for Injection Devices]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F177068-milestone-scientific-forms-china-jv-for-injection-devices%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  Milestone Scientific Inc. (MLSS.OB) has launched a JV with China National Medicines Corporation Ltd. (Sinopharm [SHA: 600511]) and Yichang Humanwell Pharmaceutical Co. Ltd., which will seek to develop orthopedic and epidural drug delivery instruments. Milestone, based in New Jersey, makes painless and precise injection devices, primarily...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 08 Dec 2009 03:21:15 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
	</item>
	<item>
		<title><![CDATA[Concord Medical IPO Coming This Week]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F176778-concord-medical-ipo-coming-this-week%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  Concord Medical Services Holdings Ltd. (NYSE: CCM), a company that operates radiation therapy and diagnostic imaging centers in China, plans to raise $126 million for its IPO on December 10. The company claims to be the largest provider of radiotherapy and diagnostic imaging services in China....]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Sun, 06 Dec 2009 07:22:58 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
	</item>
	<item>
		<title><![CDATA[Tianyin Pharma Calls for 75% Improvement in 2011]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F176551-tianyin-pharma-calls-for-75-improvement-in-2011%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:   Tianyin Pharmaceutical, Co., Inc., (NYSE Alternext: TPI), a modernized TCM company, issued guidance calling for a 75% improvement in fiscal year 2011 (ending June 30, 2011) results. The company said it expects revenue of $113 million for fiscal 2011, up from $63.6 million in 2010,...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 04 Dec 2009 02:58:53 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
	</item>
	<item>
		<title><![CDATA[Simcere Shuts Down Production in Rabies Vaccine Subsidiary over Quality Control]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F176339-simcere-shuts-down-production-in-rabies-vaccine-subsidiary-over-quality-control%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  Simcere Pharmaceutical Group (NYSE: SCR) has stopped a production line at its recently acquired vaccine subsidiary while it reviews quality control systems in the company. Simcere bought a 37.5% stake in Jiangsu Yanshen Biological Technology Stock Co. in May, and then upped its ownership to just...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 03 Dec 2009 03:27:51 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
	</item>
	<item>
		<title><![CDATA[China Sky One to Sell Diagnostic Kits in Southeast Asia]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F176112-china-sky-one-to-sell-diagnostic-kits-in-southeast-asia%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  China Sky One Medical (NSDQ: CSKI) has signed up Guangdong Mediacy Kind Medical Devices Industry Service Company to be its exclusive sales agent in Southeast Asia for two of the company&#8217;s diagnostic kits: AMI Diagnostic Kit, used to diagnose myocardial infarction, and Human Urinary Albumin Elisa...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 02 Dec 2009 02:41:25 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
		<category domain="http://resources.bnet.com/topic/china+sky+one+medical+inc..html"><![CDATA[China Sky One Medical Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CSKI</category>
		<category domain="tickers">CSKI</category>
	</item>
	<item>
		<title><![CDATA[PPD Claims to Be the 'CRO of Choice in China']]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175918-ppd-claims-to-be-the-cro-of-choice-in-china%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  In reporting that it has closed its acquisition of BioDuro, PPD, Inc. (NSDQ: PPDI) announced the acquisition cost - $77 million. The price was not previously released, nor has PPD disclosed the annual revenues of privately held BioDuro. PPD did say that, post-acquisition, it has nearly...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 01 Dec 2009 06:15:02 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+product+development+inc..html"><![CDATA[Pharmaceutical Product Development Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PPDI</category>
		<category domain="tickers">PPDI</category>
	</item>
	<item>
		<title><![CDATA[AstraZeneca's Latest Cost-Cutting Move: Offshore Production]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175916-astrazeneca-s-latest-cost-cutting-move-offshore-production%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  In a continuing attempt to cut costs, the Anglo-Swedish big pharma AstraZeneca (NYSE: AZN) said it would move all of its API production offshore, with most of it going to China. The company will close a plant in the UK that manufactures APIs for cholesterol and...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 01 Dec 2009 06:11:22 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
		<category domain="http://resources.bnet.com/topic/astrazeneca+plc..html"><![CDATA[AstraZeneca Plc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
		<category domain="tickers">AZN</category>
	</item>
	<item>
		<title><![CDATA[China Sky One Nears Approval on Two Diagnostic Tests]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175491-china-sky-one-nears-approval-on-two-diagnostic-tests%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  China Sky One Medical (NSDQ: CSKI) said it expects to have final SFDA approval for two more diagnostic kits by the end of 2009. One is a diagnostic test for Human Prostate Specific Antigen, an indicator of prostate related diseases, and the other is a determination...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 27 Nov 2009 12:29:26 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
		<category domain="http://resources.bnet.com/topic/china+sky+one+medical+inc..html"><![CDATA[China Sky One Medical Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CSKI</category>
		<category domain="tickers">CSKI</category>
	</item>
	<item>
		<title><![CDATA[Pfizer Increases R&D Commitment in China]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175392-pfizer-increases-r-d-commitment-in-china%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  Pfizer (NYSE: PFE) will expand its China R&D operations by adding facilities in central and western China, according to a Reuters story. The company will build a new clinical R&D center in Wuhan, which will support global clinical drug programs, including Phase I-IV clinical trials. Pfizer...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 26 Nov 2009 12:09:37 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Sinovac Adds Vaccine Capacity by Forming JV]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175391-sinovac-adds-vaccine-capacity-by-forming-jv%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  Sinovac Biotech (NSDQ: SVA) announced a new Joint Venture, Sinovac Dalian Vaccine Technology Co., Ltd., that will research, develop and produce human vaccines. Sinovac will contribute its vaccine expertise and capital, while Dalian Jin Gang Group will throw in land use rights, manufacturing facilities and established...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 26 Nov 2009 12:05:08 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
		<category domain="http://resources.bnet.com/topic/sinovac+biotech+ltd..html"><![CDATA[Sinovac Biotech Ltd.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SVA</category>
		<category domain="tickers">SVA</category>
	</item>
	<item>
		<title><![CDATA[GlaxoSmithKline Seeks to Commercialize Viread in China for Hepatitis B]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175261-glaxosmithkline-seeks-to-commercialize-viread-in-china-for-hepatitis-b%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  GlaxoSmithKline GSK and Gilead Sciences GILD agreed on an Asian marketing plan for their jointly owned treatment for hepatitis B, Viread® tenofovir disoproxil fumarate. GSK will have exclusive rights to commercialize the drug for hepatitis B in China. Gilead will own exclusive rights Hong Kong, Singapore,...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 25 Nov 2009 04:11:15 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/glaxosmithkline+plc..html"><![CDATA[GlaxoSmithKline Plc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
		<category domain="tickers">GILD,GSK</category>
	</item>
	<item>
		<title><![CDATA[Merck Serono to Spend $225 Million on New Beijing R&D Center]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175259-merck-serono-to-spend-225-million-on-new-beijing-r-d-center%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  Merck Serono, a division of Germany&#8217;s Merck KGaA MRK, will build a global R&D center in Beijing, China, spending $225 million over the next four years. The center, which will eventually house 200 employees, will be the fourth major R&D center for the company. The Beijing...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 25 Nov 2009 04:09:47 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[China Nuokang Bio-Pharmaceutical Banks on a Favorable U.S. IPO]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F174956-china-nuokang-bio-pharmaceutical-banks-on-a-favorable-u-s-ipo%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  China Nuokang Bio-Pharmaceutical NKBP, a company focused on hematological and cardiovascular drugs, will offer 4.5 million ADSs on the Nasdaq exchange at a price between $10 and $12. The mid-point of the range represents a $50 million debut for Nuokang. The offering gives further evidence that...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 23 Nov 2009 11:13:07 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
	</item>
</channel>
</rss>
